Sign in
SuspendedPhase 1

IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis

Key facts

Who runs it
Indapta Therapeutics, INC.
Where
Aurora, Kansas City, Orlando, St Louis, and Stanford, United StatesSee the 5 sites
Trial code
Status
Suspended
Phase
Phase 1
People taking part
34 people, planned
Started
30 Jun 2026
Expected to end
31 Dec 2028
Type of study
Interventional, 2 groups
Treatments tested
  • IDP-023
  • Ocrelizumab
  • Interleukin-2
  • Cyclophosphamide
  • Fludarabine
  • Mesna
Record updated
30 April 2025
Why it stopped
Business Reasons

Who can take part

Age
18 years to 65 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Confirmed diagnosis of primary or non-active secondary progressive MS (SPMS) based on the 2017 revisions of the McDonald criteria
  • Dosed with ocrelizumab within the prior 6 months
  • Expanded Disability Status Scale (EDSS) at screening from 3.0 to 6.5 points
  • Score of ≥2.0 on the Functional Systems (FS) scale for the pyramidal system that is due to lower extremity findings
  • Disease duration from the onset of MS symptoms:; Less than 15 years in patients with an EDSS at screening >5.0; Less than 10 years in patients with an EDSS at screening ≤5.0

Who cannot take part

  • Known presence of other neurological disorders, including but not limited to the following:; History or known presence of CNS or spinal cord tumor (e.g., meningioma, glioma); History or known presence of infectious causes of myelopathy (e.g., syphilis, Lyme disease, Human T-lymphotropic virus 1 [HTLV-1], herpes zoster myelopathy); History or known presence of systemic autoimmune disorders potentially causing progressive neurologic disease (e.g., lupus, antiphospholipid antibody syndrome, Sjögren's syndrome, Behçet's disease)
  • Impaired cardiac function or history of clinical significant cardiac disease
  • Human immunodeficiency virus (HIV) infection, active hepatitis B infection, or hepatitis C infection
  • Relapsing remitting MS at screening or active SPMS at screening
  • Inability to complete an MRI
  • Contraindication for gadolinium

Where in United States

  • University of Colorado HospitalAurora, United States
  • Kansas University Medical CenterKansas City, United States
  • AdventHealth Orlando - Adventist Health System/Sunbelt, Inc.Orlando, United States
  • Washington University in St. LouisSt Louis, United States
  • Stanford UniversityStanford, United States

About the trial

What the trial wants to find out

This is an open label, Phase 1b, multiple ascending dose, and dose-expansion study of IDP-023 administered in combination with interleukin-2 (IL-2) and ocrelizumab to evaluate the safety, tolerability, and biologic activity on autoreactive immune cells in patients with refractory progressive multiple sclerosis.

The 2 groups in the trial

  • Part 1 (dose escalation): IDP-023 in combination with IL-2 and ocrelizumabTreatment being tested

    MS patients treated with multiple doses of IDP-023 in combination with IL-2 and ocrelizumab

    Treatment: IDP-023, Ocrelizumab, Interleukin-2, Cyclophosphamide, Fludarabine, and Mesna

  • Part 2 (dose expansion): IDP-023 in combination with IL-2 and ocrelizumabTreatment being tested

    MS patients treated with the recommended dose of IDP-023 in combination with IL-2 and ocrelizumab

    Treatment: IDP-023, Ocrelizumab, Interleukin-2, Cyclophosphamide, Fludarabine, and Mesna

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase 1B Study of IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Refractory Primary and Secondary Progressive Multiple Sclerosis
Record updated
30 April 2025